Quinone Reductase Inhibitor

Quinone Reductase Inhibitors (20):

Cat. No.	Product Name	Effect	Purity

HY-N0645

Dicoumarol	Inhibitor	99.89%
Dicoumarol is an inhibitor of both NAD(P)H:quinone oxidoreductase 1 (NQO1) and PDK1 with IC₅₀s of 0.37 and 19.42 μM, respectively.

HY-100367

ES 936	Inhibitor	98.66%
ES 936 is a potent and specific NQO1 inhibitor, effective at concentrations over 1000 times lower than the non-specific inhibitor Dicoumarol (HY-N0645). NQO1 is generally considered a detoxification enzyme, capable of directly reducing quinones to hydroquinones, which in turn prevents the formation of reactive oxygen species arising from redox cycling. ES 936 can be utilized in cancer research.

HY-174807

NPB-1575	Inhibitor
NPB-1575 is a potent, orally active and brain-penetrant anti-inflammatory agent. NPB-1575 mitigates neuroinflammation and resists ferroptosis by activating the IRS2/Nrf2/NF-κB axis. NPB-1575 shows protective effect against cerebral ischemic injury and improve the neurological functional prognosis. NPB-1575 can be used for the study of ischemic stroke.

HY-12346

FH1	Inhibitor	99.17%
FH1 (NSC 12407) is a NQO2 inhibitor with hepatoprotective effects. FH1 enhances hepatocyte function and promotes differentiation of induced pluripotent stem (iPS)-derived hepatocytes to a more mature phenotype and maturation of well-differentiated hepatocyte-like cell (iHeps) cultures. FH1 protects against Acetaminophen (HY-66005)-induced hepatotoxicity in both embryos and adult zebrafish.

HY-13543

Tretazicar	Inhibitor	99.65%
Tretazicar (CB 1954), an antitumor proagent, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1).

HY-15673

KP372-1	Inhibitor	99.5%
KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer).

HY-N0606

Ginsenoside Rh3	Inhibitor	99.95%
Ginsenoside Rh3 is a bacterial metabolite of Ginsenoside Rg5. Ginsenoside Rh3 treatment in human retinal cells induces Nrf2 activation.

HY-108992

Deoxynyboquinone	Inhibitor	99.21%
Deoxynyboquinone, an excellent NQO1 substrate, is a potent antineoplastic agent. Deoxynyboquinone induces apoptosis in cancer cell lines. Deoxynyboquinone kills cancer cells through oxidative stress and reactive oxygen species (ROS) formation.

HY-N7335

Dehydroglyasperin C	Inhibitor	99.12%
Dehydroglyasperin C, a isoflavone, is a potent NAD(P)H:oxidoquinone reductase (NQO1) and phase 2 enzyme inducer. Dehydroglyasperin C has antioxidant, neuroprotective, cancer chemopreventive, and anti-inflammatory activities.

HY-118588

Diminutol	Inhibitor	98.1%
Diminutol is an inhibitor for NADP-dependent quinone oxidoreductase (NQO1), that is involved in microtubule morphogenesis and cell devision.

HY-170301

Keap1-IN-1	Inhibitor
Keap1-IN-1 (Compound 27) is the inhibitor for Keap1, that covalently modifys the Cys151 site in the BTB domain of KEAP1, and interfers with the interaction between Keap-Nrf. Keap1-IN-1 upregulates the mRNA expression of the antioxidant stress element (ARE)-dependent gene NQO1 with an EC₅₀ of 160 nM. Keap1-IN-1 exhibits cytotoxicity in cell U2OS with an EC₅₀ of 527 nM.

HY-171035

PRL-295	Inhibitor
PRL-295 is an orally active inhibitor targeting Keap1-Nrf2 interaction. PRL-295 increases the thermal stability of Keap1 and disrupts its interaction with Nrf2, thereby activating the Nrf2-dependent transcriptional target NAD(P)H:quinone oxidoreductase 1 (NQO1). PRL-295 protects against Acetaminophen (HY-66005)-induced liver injury in mice.

HY-RS09523

NQO1 Human Pre-designed siRNA Set A	Inhibitor
NQO1 Human Pre-designed siRNA Set A contains three designed siRNAs for NQO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-170947

Antitumor agent-195	Inhibitor
Antitumor agent-195 (compound 16c) is a dual targeting agent of STAT3 and NQO1. Antitumor agent-195 significantly inhibits phosphorylation of STAT3 at Tyr705 at a concentration of 1 μM and effectively induce Apoptosis in MDAMB-231 and MDA-MB-468 breast cancer cells. Antitumor agent-195 as a NQO1 substrate strongly increases ROS generation and causes severe DNA damage in a dose-dependent manner. Antitumor agent-195 shows encouraging anti-tumor efficacy in the MDA-MB-231 xenograft model.

HY-169842

NSC 645827	Inhibitor
NSC 645827 is an inhibitor for NAD(P)H: quinone oxidoreductase 1 (NQO1) with an IC₅₀ of 0.7 μM.

HY-RS22982

Nqo1 Rat Pre-designed siRNA Set A	Inhibitor
Nqo1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nqo1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS16549

Nqo1 Mouse Pre-designed siRNA Set A	Inhibitor
Nqo1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nqo1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-N14947

Pterulinic acid	Inhibitor
Pterulinic acid is a coenzyme I: Coenzyme Q oxidoreductase inhibitor. he IC₅₀ (μg/mL) L1210 and HL60 of Pterulinic acid to mammalian cell lines are 50 and 20 respectively. HeLaS3 25; BHK is 100.

HY-N14897

Pterulone	Inhibitor
Pterulone is a coenzyme I: Coenzyme Q oxidoreductase inhibitor found in fungus Pterula SP.82168.

HY-147548

Keap1-Nrf2-IN-10	Inhibitor
Keap1-Nrf2-IN-10 (compound 15) is a potent NQO1 inducer. Keap1-Nrf2-IN-10 inhibits oxidative stress by decreasing the levels of MDA, ROS, NQO1 in the liver for gamma-irradiated mice. Keap1-Nrf2-IN-10 improves the survival of gamma-irradiated mice.

Name
Email *

	Sorry, but the email address you supplied was invalid.